A urinary microRNA (miR) signature for diagnosis of bladder cancer

Bladder cancer is the ninth most common malignancy worldwide, with an estimated 429,000 new cases diagnosed annually. At the time of diagnosis, the majority of tumors are well differentiated and do not invade the bladder's detrusor muscle, so called low-grade non-muscle invasive bladder cancer (LGNMIBC). Despite aggressive treatment by transurethral resection and intravesical instillations, LGNMIBC recurs in approximately 50% of patients. However, these tumors rarely progress to a higher grade or stage and have therefore an excellent prognosis [1].
Source: Urologic Oncology: Seminars and Original Investigations - Category: Urology & Nephrology Authors: Tags: Original article Source Type: research